Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Polymeric Nanoparticles for the Delivery of miRNA to Treat Chronic Obstructive Pulmonary Disease (COPD).

Mohamed, A, Kunda, NK, Ross, K, Hutcheon, GA and Saleem, IY (2019) Polymeric Nanoparticles for the Delivery of miRNA to Treat Chronic Obstructive Pulmonary Disease (COPD). European Journal of Pharmaceutics and Biopharmaceutics, 136. pp. 1-8. ISSN 1873-3441

[img]
Preview
Text
EJPB_2018_843_Revision 1_V0(2).pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

RNA interference (RNAi) based therapeutics are considered an endogenous mechanism for modulating gene expression. In addition, microRNAs (miRNAs) may be tractable targets for the treatment of Chronic Obstructive Pulmonary Disease (COPD). In this study miR146a was adsorbed onto poly (glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL, nanoparticles (NPs) to reduce target gene IRAK1 expression. NPs were prepared using an oil-in-water single emulsion solvent evaporation method incorporating cationic lipid dioleoyltrimethylammoniumpropane (DOTAP). This resulted in NPs of 244.80±4.40 nm at 15 % DOTAP concentration, zeta potential (ZP) of +14.8±0.26 mV and miR-146a (40 µg/ml) maximum adsorption onto 15 % DOTAP NPs was 36.25±0.35 µg per 10 mg NP following 24 h incubation. Using the MTT assay, it was observed that over 75 % at 0.312 mg/ml of A549 cells remained viable after 18 h exposure to cationic NPs at a concentration of 1.25 mg/ml. Furthermore, the in vitro release profile of miR-146a from loaded NPs showed a continuous release up to 77 % after 24 h. Internalization of miR-146a loaded cationic NPs was observed in A549 cell lines using fluorescence and confocal microscopy. The miR146a delivered as miR-146a-NPs had a dose dependent effect of highest NPs concentrations 0.321 and 0.625 mg/ml and reduced target gene IRAK1 expression to 40 %. In addition, IL-8 promoter reporter output (GFP) was dampened by miR-146a-NPs. In conclusion, miR-146a was successfully adsorbed onto PGA-co-PDL-DOTAP NPs and the miR-146a retained biological activity. Therefore, these results demonstrate the potential of PGA-co-PDL NPs as a delivery system for miR-146a to treat COPD.

Item Type: Article
Uncontrolled Keywords: 1115 Pharmacology and Pharmaceutical Sciences
Subjects: Q Science > QD Chemistry
R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Elsevier
Related URLs:
Date Deposited: 08 Feb 2019 15:43
Last Modified: 04 Sep 2021 09:47
DOI or ID number: 10.1016/j.ejpb.2019.01.002
URI: https://researchonline.ljmu.ac.uk/id/eprint/9990
View Item View Item